538 related articles for article (PubMed ID: 15271413)
1. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
2. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
[TBL] [Abstract][Full Text] [Related]
3. Clinical manifestations of familial medullary thyroid carcinoma.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):348-50. PubMed ID: 15271414
[TBL] [Abstract][Full Text] [Related]
4. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.
Jindrichová S; Vcelák J; Vlcek P; Neradilová M; Nemec J; Bendlová B
J Endocrinol; 2004 Nov; 183(2):257-65. PubMed ID: 15531714
[TBL] [Abstract][Full Text] [Related]
5. [Hereditary medullary thyroid carcinoma--genotype-phenotype characterization].
Frank-Raue K; Heimbach C; Rondot S; Usadel KH; Meng W; Varma C; Fuchs-Hammoser R; Höppner W; Schulze E; Raue F
Dtsch Med Wochenschr; 2003 Sep; 128(39):1998-2002. PubMed ID: 14508694
[TBL] [Abstract][Full Text] [Related]
6. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
[TBL] [Abstract][Full Text] [Related]
7. [Neural crest and multiple endocrinopathies].
Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
[TBL] [Abstract][Full Text] [Related]
8. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.
Shirahama S; Ogura K; Takami H; Ito K; Tohsen T; Miyauchi A; Nakamura Y
J Hum Genet; 1998; 43(2):101-6. PubMed ID: 9621513
[TBL] [Abstract][Full Text] [Related]
10. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
[TBL] [Abstract][Full Text] [Related]
12. [Multiple endocrine neoplasia type 2A, type 2B and familial medullary thyroid carcinoma syndrome].
Obara T; Yamashita T; Kanbe M; Ito Y; Egawa S; Yamaguchi K
Nihon Rinsho; 1995 Nov; 53(11):2708-15. PubMed ID: 8538031
[TBL] [Abstract][Full Text] [Related]
13. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families.
Marsh DJ; Robinson BG; Andrew S; Richardson AL; Pojer R; Schnitzler M; Mulligan LM; Hyland VJ
Genomics; 1994 Sep; 23(2):477-9. PubMed ID: 7835899
[TBL] [Abstract][Full Text] [Related]
14. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
15. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
Fitze G; Saeger HD; Roesner D; Schackert HK
Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.
Frank-Raue K; Rondot S; Raue F
Mol Cell Endocrinol; 2010 Jun; 322(1-2):2-7. PubMed ID: 20083156
[TBL] [Abstract][Full Text] [Related]
17. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB
Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527
[TBL] [Abstract][Full Text] [Related]
18. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A.
Chung YJ; Kim HH; Kim HJ; Min YK; Lee MS; Lee MK; Kim KW; Ki CS; Kim JW; Chung JH
Thyroid; 2004 Oct; 14(10):813-8. PubMed ID: 15588376
[TBL] [Abstract][Full Text] [Related]
19. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
Frank-Raue K; Rondot S; Schulze E; Raue F
Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
[TBL] [Abstract][Full Text] [Related]
20. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
